Risk reduction endpoints should be part of the design of adjuvant therapy clinical trials for patients with melanoma: A commentary

Abstract

Selected chemotherapy or immunotherapy agents with potential adjuvant activity in patients with melanoma may also reduce the risk of a second primary malignancy. Adjuvant trials employing such agents should be designed to prospectively record both adjuvant and risk reduction endpoints in the same patients.